查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1293021

醫療用大麻的全球市場 - 產業趨勢與預測(～2030年)

Global Medical Cannabis Market - Industry Trends and Forecast to 2030
出版日期: | 出版商: Data Bridge Market Research | 英文 1527 Pages | 商品交期: 請詢問到貨日

價格

全球醫用大麻市場規模預計將從 2022 年的 172.1802 億美元增至 2030 年的 884.8801 億美元，2023-2030 年預測期間複合年增長率為 22.76%。

本報告提供全球醫療用大麻市場相關調查分析，提供產業趨勢與預測，促進因素與阻礙因素，市場區隔的分析等資訊。

目錄

第1章 簡介

第2章 市場區隔

第3章 摘要整理

第4章 主要考察

  • PESTEL分析
  • 波特的五力分析

第5章 產業的考察

  • 專利分析
  • 藥物治療率:各成熟市場
  • 人口動態趨勢:全部的罹患率的影響
  • 患者流通量圖
  • 主要的價格策略
  • 主要的病患註冊策略

第6章 法規Scenario

  • 美國
  • 加拿大
  • 墨西哥
  • 德國
  • 義大利
  • 英國
  • 瑞士
  • 法國
  • 俄羅斯
  • 西班牙
  • 匈牙利
  • 比利時
  • 澳洲
  • 泰國
  • 日本
  • 中國
  • 紐西蘭
  • 新加坡
  • 印度
  • 馬來西亞
  • 菲律賓
  • 巴西
  • 阿根廷
  • 南非
  • 阿拉伯聯合大公國

第7章 市場概要

  • 促進因素
    • 大麻在醫學上的使用增加
    • 大麻合法化
    • 主要公司的戰略努力
    • 需要使用大麻的疾病流行
  • 阻礙因素
    • 大麻使用的複雜監管結構
    • 長期使用的不良反應
    • 購買昂貴的商品和優質的產品
  • 機會
    • 通過增加研發活動來開發創新產品
    • 擴大採用大麻來獲取快樂
    • 老年人口增加
  • 課題
    • 大麻黑市的興起
    • 與使用大麻相關的副作用
    • 技術人才短缺

第8章 全球醫療用大麻市場:各產品

  • 概要
  • 油
  • 醫用乾大麻
  • 醫用大麻膠囊
  • 電子煙筆
  • 花
  • 保濕霜
  • 地花
  • 修補
  • 面膜精華液
  • 潔膚護理
  • 其他

第9章 全球醫療用大麻市場:類別

  • 概要
  • Sativa
  • 混合
  • Indica

第10章 按全球醫療用大麻市場:衍生物

  • 概要
  • 大麻二酚 (CBD)
  • 四氫大麻酚 (THC)/Delta 8 四氫大麻酚
  • 大麻醇 (CBG)
  • 大麻環烯 (CBC)
  • 大麻酚 (CBN)
  • 大麻二氯 (CBL)
  • 其他

第11章 全球醫療用大麻市場:各用途

  • 概要
  • 疼痛管理
  • 不安

The global medical cannabis market is expected to reach USD 88,488.01 million by 2030 from USD 17,218.02 million in 2022, growing at a CAGR of 22.76% during the forecast period of 2023 to 2030.

Market Segmentation

Global Medical Cannabis Market, By Product (Oil, Medical Cannabis Capsules, Patch, Whole Flower, Ground Flower, Vape Pen, Dried Medical Cannabis, Creams & Moisturizer, Masks & Serum, Cleanser, and Others), Source (Natural and Synthetic), Species (Cannabis Indica, Sativa, and Hybrid), Application (Alzheimer's Disease, Appetite Loss, Cancer, Inflammatory Bowel Diseases, Eating Disorders, Epilepsy, Autism, Mental Health Conditions, Multiple Sclerosis, Pain Management, Nausea, Muscle Spasms, Wasting Syndrome (Cachexia), Elevate Mood, Depression and Sleep Disorders, Anxiety, and Others), Derivatives (Cannabidiol (CBD), Tetrahydrocannabinol (THC), Delta-8-tetrahydrocannabinol, Cannabinol (CBN), Cannabicyclol (CBL), Cannabichromene (CBC), Cannabigerol (CBG), and Others), Treatment Type (Expectorant, Antiviral, Analgesic, Aphrodisiac, Psychedelic, and Others), Route of Administration (Oral Solutions and Capsules, Smoking, Vaporizers, Topicals, and Others), End User (Pharmaceutical Industry, Research and Development Centers, Homecare Setting, Hospital, Rehab Centers, and Others), Distribution Channel (B2B and B2C), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Netherlands, Russia, Denmark, Switzerland, Turkey, Sweden, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, New Zealand, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Ethiopia, U.A.E., and Rest of Middle East and Africa) - Industry Trends and Forecast to 2030.

Overview of Global Medical Cannabis Market Dynamics

Driver

Increased medical use of cannabis

Restraint

The complex regulatory structure for the usage of cannabis

Opportunity

Novel product development with increasing R&D activities

Market Players

Some of the major market players operating in the global medical cannabis market are:

  • MediPharm Labs Inc.
  • Tilray
  • Aurora Cannabis
  • JAZZ Pharmaceuticals Inc. (GW Pharmaceuticals plc)
  • HEXO Corp. (Zenabis Global Ltd)
  • Cresco Labs
  • Peace Naturals Project Inc.
  • CANOPY GROWTH CORPORATION
  • Medical Marijuana, Inc.
  • Seed Cellar
  • EcoGen Biosciences
  • CANNABIS SEEDS USA
  • Seeds For Me
  • HUMBOLDT SEED COMPANY
  • Extractas
  • World Class Cannabis Seeds (Crop King Seeds)
  • BARNEY'S FARM
  • FOLIUM BIOSCIENCES
  • PharmaHemp
  • Elixinol Global Limited
  • ENDOCA
  • Harmony
  • MARY'S nutritionals, LLC
  • Pure Ratios
  • Greenwich Biosciences, Inc.
  • Upstate Elevator Supply Co.
  • Apothecanna
  • BOL Pharma
  • IDT Australia

TABLE OF CONTENTS

1 INTRODUCTION 157

  • 1.1 OBJECTIVES OF THE STUDY 157
  • 1.2 MARKET DEFINITION 157
  • 1.3 OVERVIEW OF THE GLOBAL MEDICAL CANNABIS MARKET 157
  • 1.4 LIMITATIONS 159
  • 1.5 MARKETS COVERED 160

2 MARKET SEGMENTATION 169

  • 2.1 MARKETS COVERED 169
  • 2.2 GEOGRAPHICAL SCOPE 170
  • 2.3 YEARS CONSIDERED FOR THE STUDY 171
  • 2.4 CURRENCY AND PRICING 171
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL 172
  • 2.6 MULTIVARIATE MODELLING 175
  • 2.7 PRODUCT LIFELINE CURVE 175
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 176
  • 2.9 DBMR MARKET POSITION GRID 177
  • 2.10 MARKET APPLICATION COVERAGE GRID 179
  • 2.11 VENDOR SHARE ANALYSIS 180
  • 2.12 SECONDARY SOURCES 181
  • 2.13 ASSUMPTIONS 181

3 EXECUTIVE SUMMARY 182

4 PREMIUM INSIGHTS 185

  • 4.1 PESTEL ANALYSIS 188
  • 4.2 PORTER'S FIVE FORCES 189

5 INDUSTRY INSIGHTS 190

  • 5.1 INDUSTRY INSIGHTS PATENT ANALYSIS 190
  • 5.2 DRUG TREATMENT RATE BY MATURED MARKETS 197
  • 5.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 198
  • 5.4 PATIENT FLOW DIAGRAM 199
  • 5.5 KEY PRICING STRATEGIES 200
  • 5.6 KEY PATIENT ENROLLMENT STRATEGIES 201

6 REGULATORY SCENARIO 202

  • 6.1 U.S. 202
  • 6.2 CANADA 202
  • 6.3 MEXICO 202
  • 6.4 GERMANY 203
  • 6.5 ITALY 203
  • 6.6 U.K. 203
  • 6.7 SWITZERLAND 203
  • 6.8 FRANCE 203
  • 6.9 RUSSIA 203
  • 6.10 SPAIN 203
  • 6.11 HUNGARY 203
  • 6.12 BELGIUM 203
  • 6.13 AUSTRALIA 204
  • 6.14 THAILAND 204
  • 6.15 JAPAN 204
  • 6.16 CHINA 204
  • 6.17 NEW ZEALAND 204
  • 6.18 SINGAPORE 204
  • 6.19 INDIA 204
  • 6.20 MALAYSIA 205
  • 6.21 PHILIPPINES 205
  • 6.22 BRAZIL 205
  • 6.23 ARGENTINA 205
  • 6.24 SOUTH AFRICA 205
  • 6.25 U.A.E. 205

7 MARKET OVERVIEW 206

  • 7.1 DRIVERS 207
    • 7.1.1 INCREASED USE OF CANNABIS IN MEDICINES 207
    • 7.1.2 LEGALIZATION OF CANNABIS 207
    • 7.1.3 STRATEGIC INITIATIVES TAKEN BY KEY PLAYERS 207
    • 7.1.4 RISE IN THE PREVALENCE OF DISEASES THAT REQUIRE THE USE OF CANNABIS 208
  • 7.2 RESTRAINTS 209
    • 7.2.1 COMPLEX REGULATORY STRUCTURE FOR THE USAGE OF CANNABIS 209
    • 7.2.2 ADVERSE EFFECTS DUE TO LONG-TERM USE 209
    • 7.2.3 HIGH-COST PURCHASING AND RUSH FOR PREMIUM QUALITY 210
  • 7.3 OPPORTUNITIES 210
    • 7.3.1 NOVEL PRODUCT DEVELOPMENT WITH INCREASING R&D ACTIVITIES 210
    • 7.3.2 INCREASED ADOPTION OF CANNABIS FOR RECREATIONAL PURPOSES 210
    • 7.3.3 GROWING GERIATRIC POPULATION 211
  • 7.4 CHALLENGES 211
    • 7.4.1 RISE OF THE CANNABIS BLACK MARKET 211
    • 7.4.2 SIDE EFFECTS RELATED TO THE USE OF CANNABIS 212
    • 7.4.3 SHORTAGE OF SKILLED PERSONNEL 212

8 GLOBAL MEDICAL CANNABIS MARKET, BY PRODUCT 213

  • 8.1 OVERVIEW 214
  • 8.2 OIL 218
    • 8.2.1 OIL, BY TYPE 218
      • 8.2.1.1 CBD OIL CONCENTRATES 218
      • 8.2.1.2 CBD VAPE OIL 219
      • 8.2.1.3 CBD TINCTURES 219
    • 8.2.2 OIL, BY SOURCE 219
      • 8.2.2.1 HEMP BASED 219
      • 8.2.2.2 MARIJUANA BASED 219
    • 8.2.3 OIL, BY SPECIES 219
      • 8.2.3.1 SATIVA 219
      • 8.2.3.2 HYBRID 220
      • 8.2.3.3 CANNABIS INDICA 220
    • 8.2.4 OIL, BY PRODUCT TYPE 220
      • 8.2.4.1 BRANDED 220
        • 8.2.4.1.1 PENGUIN CBD OIL 220
        • 8.2.4.1.2 FAB CBD OIL 221
        • 8.2.4.1.3 GREEN ROADS BROAD SPECTRUM CBD OIL 221
        • 8.2.4.1.4 OTHERS 221
      • 8.2.4.2 GENERIC 221
  • 8.3 DRIED MEDICAL CANNABIS 221
    • 8.3.1 CANNABIS INDICA 222
    • 8.3.2 SATIVA 222
    • 8.3.3 HYBRID 222
  • 8.4 MEDICAL CANNABIS CAPSULES 223
    • 8.4.1 MEDICAL CANNABIS CAPSULES, BY TYPE 223
      • 8.4.1.1 OIL BASED CANNABIS CAPSULES 224
      • 8.4.1.2 POWDER BASED CANNABIS CAPSULES 224
      • 8.4.1.3 LIQUID BASED CANNABIS CAPSULES 224
      • 8.4.1.4 OTHERS 224
    • 8.4.2 MEDICAL CANNABIS CAPSULES, BY CONCENTRATES 224
      • 8.4.2.1 HIGH CBD CAPSULES DIGITAL 224
      • 8.4.2.2 HIGH THC CAPSULE 224
      • 8.4.2.3 THC/CBD BALANCED CAPSULE 225
      • 8.4.2.4 CBD ISOLATE CAPSULE 225
    • 8.4.3 MEDICAL CANNABIS CAPSULES, BY SPECIES 225
      • 8.4.3.1 SATIVA 225
      • 8.4.3.2 CANNABIS INDICA 225
    • 8.4.4 MEDICAL CANNABIS CAPSULES, BY PRODUCT TYPE 225
      • 8.4.4.1 BRANDED 226
        • 8.4.4.1.1 JOY NUTRITION 226
        • 8.4.4.1.2 MEDTERRA ISOLATE CBD GEL CAPSULES 226
        • 8.4.4.1.3 LAZARUS NATURALS 226
        • 8.4.4.1.4 OTHERS 226
      • 8.4.4.2 GENERIC 226
  • 8.5 VAPE PEN 226
    • 8.5.1 VAPE PEN, BY SPECIES 227
      • 8.5.1.1 SATIVA 227
      • 8.5.1.2 HYBRID 227
      • 8.5.1.3 CANNABIS INDICA 228
    • 8.5.2 VAPE PEN, BY PRODUCT TYPE 228
      • 8.5.2.1 BRANDED 228
        • 8.5.2.1.1 KANDYPENS RUBI 228
        • 8.5.2.1.2 SOL E-NECTAR COLLECTOR 228
        • 8.5.2.1.3 PAX ERA PRO-OIL VAPE PEN 229
      • 8.5.2.2 GENERIC 229
  • 8.6 WHOLE FLOWER 229
    • 8.6.1 WHOLE FLOWER, SPECIES 229
      • 8.6.1.1 SATIVA 230
      • 8.6.1.2 HYBRID 230
      • 8.6.1.3 CANNABIS INDICA 230
    • 8.6.2 WHOLE FLOWER, PRODUCT TYPE 230
      • 8.6.2.1 BRANDED 231
        • 8.6.2.1.1 ASTER FARMS 231
        • 8.6.2.1.2 RA FLOWER 231
        • 8.6.2.1.3 BAD APPLE 231
      • 8.6.2.2 GENERIC 231
  • 8.7 CREAMS & MOISTURIZER 232
    • 8.7.1 CREAMS & MOISTURIZER, BY SPECIES 232
      • 8.7.1.1 SATIVA 233
      • 8.7.1.2 HYBRID 233
      • 8.7.1.3 CANNABIS INDICA 233
    • 8.7.2 CREAMS & MOISTURIZER, BY PRODUCT TYPE 233
      • 8.7.2.1 BRANDED 233
        • 8.7.2.1.1 CBDFX MUSCLE & JOINT 234
        • 8.7.2.1.2 ASPEN GREEN MUSCLE RELIEF COOLING CREAM 234
        • 8.7.2.1.3 MEDTERRA PAIN CREAM 234
      • 8.7.2.2 GENERIC 234
  • 8.8 GROUND FLOWER 234
    • 8.8.1 GROUND FLOWER, BY SPECIES 235
      • 8.8.1.1 SATIVA 235
      • 8.8.1.2 HYBRID 235
      • 8.8.1.3 CANNABIS INDICA 235
    • 8.8.2 GROUND FLOWER, BY PRODUCT TYPE 235
      • 8.8.2.1 BRANDED 236
        • 8.8.2.1.1 ASTER FARMS 236
        • 8.8.2.1.2 RA FLOWER 236
        • 8.8.2.1.3 BAD APPLE 236
      • 8.8.2.2 GENERIC 236
  • 8.9 PATCH 237
    • 8.9.1 PATCH, BY TYPE 237
      • 8.9.1.1 RESERVOIR 237
      • 8.9.1.2 LAYER DRUG-IN-ADHESIVE 237
      • 8.9.1.3 OTHERS 238
    • 8.9.2 PATCH, BY SPECIES 238
      • 8.9.2.1 SATIVA 238
      • 8.9.2.2 CANNABIS INDICA 238
      • 8.9.2.3 HYBRID 238
    • 8.9.3 PATCH, BY PRODUCT TYPE 238
      • 8.9.3.1 BRANDED 238
        • 8.9.3.1.1 HEMP BOMBS 239
        • 8.9.3.1.2 PUREKANA 239
        • 8.9.3.1.3 PURE RATIOS 239
        • 8.9.3.1.4 RESERVOIR 239
      • 8.9.3.2 GENERIC 239
  • 8.10 MASKS & SERUM 240
    • 8.10.1 MASKS & SERUM, BY SPECIES 240
      • 8.10.1.1 SATIVA 241
      • 8.10.1.2 CANNABIS INDICA 241
      • 8.10.1.3 HYBRID 241
    • 8.10.2 MASKS & SERUM, BY PRODUCT TYPE 241
      • 8.10.2.1 BRANDED 241
        • 8.10.2.1.1 BUMP & SMOOTH CBD 241
        • 8.10.2.1.2 FACIAL ESSENCE 242
        • 8.10.2.1.3 OTHERS 242
      • 8.10.2.2 GENERIC 242
  • 8.11 CLEANSER 242
    • 8.11.1 CLEANSER, BY SPECIES 242
      • 8.11.1.1 SATIVA 243
      • 8.11.1.2 HYBRID 243
      • 8.11.1.3 CANNABIS INDICA 243
    • 8.11.2 CLEANSER, BY PRODUCT TYPE 243
      • 8.11.2.1 BRANDED 244
        • 8.11.2.1.1 KIEHL'S 244
        • 8.11.2.1.2 CBD 101 244
        • 8.11.2.1.3 OTHERS 244
      • 8.11.2.2 GENERIC 244
  • 8.12 OTHERS 245

9 GLOBAL MEDICAL CANNABIS MARKET, BY SPECIES 246

  • 9.1 OVERVIEW 247
  • 9.2 SATIVA 250
  • 9.3 HYBRID 251
  • 9.4 CANNABIS INDICA 252

10 GLOBAL MEDICAL CANNABIS MARKET, BY DERIVATIVES 253

  • 10.1 OVERVIEW 254
  • 10.2 CANNABIDIOL (CBD) 257
  • 10.3 TETRAHYDROCANNABINOL (THC)/DELTA-8-TETRAHYDROCANNABINOL 257
  • 10.4 CANNABIGEROL (CBG) 258
  • 10.5 CANNABICHROMENE (CBC) 259
  • 10.6 CANNABINOL (CBN) 260
  • 10.7 CANNABICYCLOL (CBL) 261
  • 10.8 OTHERS 262

11 GLOBAL MEDICAL CANNABIS MARKET, BY APPLICATION 263

  • 11.1 OVERVIEW 264
  • 11.2 PAIN MANAGEMENT 268
    • 11.2.1 PAIN MANAGEMENT, BY TYPE 268
      • 11.2.1.1 CHRONIC PAIN 268
      • 11.2.1.2 NON-CANCER CHRONIC PAIN 269
      • 11.2.1.3 NEUROLOGICAL PAIN 269
    • 11.2.2 PAIN MANAGEMENT, BY PRODUCT 269
      • 11.2.2.1 OIL 269
      • 11.2.2.2 DRIED MEDICAL CANNABIS 269
      • 11.2.2.3 MEDICAL CANNABIS CAPSULES 269
      • 11.2.2.4 PATCH 270
      • 11.2.2.5 GROUND FLOWER 270
      • 11.2.2.6 CREAMS & MOISTURIZER 270
      • 11.2.2.7 VAPE PEN 270
      • 11.2.2.8 WHOLE FLOWER 270
      • 11.2.2.9 MASKS & SERUM 270
      • 11.2.2.10 CLEANSER 270
      • 11.2.2.11 OTHERS 270
  • 11.3 ANXIETY 270
    • 11.3.1 OIL 271
    • 11.3.2 DRIED MEDICAL CANNABIS 271
    • 11.3.3 MEDICAL CANNABIS CAPSULES 272
    • 11.3.4 PATCH 272
    • 11.3.5 GROUND FLOWER 272
    • 11.3.6 CREAMS & MOISTURIZER 272
    • 11.3.7 VAPE PEN 272
    • 11.3.8 WHOLE FLOWER 272
    • 11.3.9 MASKS & SERUM 272
    • 11.3.10 CLEANSER 272
    • 11.3.11 OTHERS 272
  • 11.4 MUSCLE SPASM 273
    • 11.4.1 OIL 274
    • 11.4.2 DRIED MEDICAL CANNABIS 274
    • 11.4.3 MEDICAL CANNABIS CAPSULES 274
    • 11.4.4 PATCH 274
    • 11.4.5 GROUND FLOWER 274
    • 11.4.6 CREAMS & MOISTURIZER 274
    • 11.4.7 VAPE PEN 275
    • 11.4.8 WHOLE FLOWER 275
    • 11.4.9 MASKS & SERUM 275
    • 11.4.10 CLEANSER 275
    • 11.4.11 OTHERS 275
  • 11.5 NAUSEA 275
    • 11.5.1 OIL 276
    • 11.5.2 DRIED MEDICAL CANNABIS 276
    • 11.5.3 MEDICAL CANNABIS CAPSULES 276
    • 11.5.4 PATCH 276
    • 11.5.5 GROUND FLOWER 276
    • 11.5.6 CREAMS & MOISTURIZER 277
    • 11.5.7 VAPE PEN 277
    • 11.5.8 WHOLE FLOWER 277
    • 11.5.9 MASKS & SERUM 277
    • 11.5.10 CLEANSER 277
    • 11.5.11 OTHERS 277
  • 11.6 APPETITE LOSS 277
    • 11.6.1 OIL 278
    • 11.6.2 DRIED MEDICAL CANNABIS 278
    • 11.6.3 MEDICAL CANNABIS CAPSULES 279
    • 11.6.4 PATCH 279
    • 11.6.5 GROUND FLOWER 279
    • 11.6.6 CREAMS & MOISTURIZER 279
    • 11.6.7 VAPE PEN 279
    • 11.6.8 WHOLE FLOWER 279
    • 11.6.9 MASKS & SERUM 279
    • 11.6.10 CLEANSER 279
    • 11.6.11 OTHERS 279
  • 11.7 EATING DISORDERS 280
    • 11.7.1 OIL 281
    • 11.7.2 DRIED MEDICAL CANNABIS 281
    • 11.7.3 MEDICAL CANNABIS CAPSULES 281
    • 11.7.4 PATCH 281
    • 11.7.5 GROUND FLOWER 281
    • 11.7.6 CREAMS & MOISTURIZER 282
    • 11.7.7 VAPE PEN 282
    • 11.7.8 WHOLE FLOWER 282
    • 11.7.9 MASKS & SERUM 282
    • 11.7.10 CLEANSER 282
    • 11.7.11 OTHERS 282
  • 11.8 INFLAMMATORY BOWEL DISEASES 282
    • 11.8.1 OIL 283
    • 11.8.2 DRIED MEDICAL CANNABIS 283
    • 11.8.3 MEDICAL CANNABIS CAPSULES 284
    • 11.8.4 PATCH 284
    • 11.8.5 GROUND FLOWER 284
    • 11.8.6 CREAMS & MOISTURIZER 284
    • 11.8.7 VAPE PEN 284
    • 11.8.8 WHOLE FLOWER 284
    • 11.8.9 MASKS & SERUM 284
    • 11.8.10 CLEANSER 284
    • 11.8.11 OTHERS 284
  • 11.9 CANCER 285
    • 11.9.1 OIL 286
    • 11.9.2 DRIED MEDICAL CANNABIS 286
    • 11.9.3 MEDICAL CANNABIS CAPSULES 286
    • 11.9.4 PATCH 286
    • 11.9.5 GROUND FLOWER 286
    • 11.9.6 CREAMS & MOISTURIZER 287
    • 11.9.7 VAPE PEN 287
    • 11.9.8 WHOLE FLOWER 287
    • 11.9.9 MASKS & SERUM 287
    • 11.9.10 CLEANSER 287
    • 11.9.11 OTHERS 287
  • 11.10 ARTHRITIS 287
    • 11.10.1 OIL 288
    • 11.10.2 DRIED MEDICAL CANNABIS 288
    • 11.10.3 MEDICAL CANNABIS CAPSULES 288
    • 11.10.4 PATCH 288
    • 11.10.5 GROUND FLOWER 288
    • 11.10.6 CREAMS & MOISTURIZER 289
    • 11.10.7 VAPE PEN 289
    • 11.10.8 WHOLE FLOWER 289
    • 11.10.9 MASKS & SERUM 289
    • 11.10.10 CLEANSER 289
    • 11.10.11 OTHERS 289
  • 11.11 WASHING SYNDROME (CACHEXIA) 289
    • 11.11.1 OIL 290
    • 11.11.2 DRIED MEDICAL CANNABIS 290
    • 11.11.3 MEDICAL CANNABIS CAPSULES 290
    • 11.11.4 PATCH 290
    • 11.11.5 GROUND FLOWER 290
    • 11.11.6 CREAMS & MOISTURIZER 291
    • 11.11.7 VAPE PEN 291
    • 11.11.8 WHOLE FLOWER 291
    • 11.11.9 MASKS & SERUM 291
    • 11.11.10 CLEANSER 291
    • 11.11.11 OTHERS 291
  • 11.12 ALZHEIMER'S DISEASE 291
    • 11.12.1 OIL 292
    • 11.12.2 DRIED MEDICAL CANNABIS 292
    • 11.12.3 MEDICAL CANNABIS CAPSULES 293
    • 11.12.4 PATCH 293
    • 11.12.5 GROUND FLOWER 293
    • 11.12.6 CREAMS & MOISTURIZER 293
    • 11.12.7 VAPE PEN 293
    • 11.12.8 WHOLE FLOWER 293
    • 11.12.9 MASKS & SERUM 293
    • 11.12.10 CLEANSER 293
    • 11.12.11 OTHERS 293
  • 11.13 EPILEPSY 294
    • 11.13.1 OIL 295
    • 11.13.2 DRIED MEDICAL CANNABIS 295
    • 11.13.3 MEDICAL CANNABIS CAPSULES 295
    • 11.13.4 PATCH 295
    • 11.13.5 GROUND FLOWER 295
    • 11.13.6 CREAMS & MOISTURIZER 296
    • 11.13.7 VAPE PEN 296
    • 11.13.8 WHOLE FLOWER 296
    • 11.13.9 MASKS & SERUM 296
    • 11.13.10 CLEANSER 296
    • 11.13.11 OTHERS 296
  • 11.14 DEPRESSION AND SLEEP DISORDER 296
    • 11.14.1 OIL 297
    • 11.14.2 DRIED MEDICAL CANNABIS 297
    • 11.14.3 MEDICAL CANNABIS CAPSULES 298
    • 11.14.4 PATCH 298
    • 11.14.5 GROUND FLOWER 298
    • 11.14.6 CREAMS & MOISTURIZER 298
    • 11.14.7 VAPE PEN 298
    • 11.14.8 WHOLE FLOWER 298
    • 11.14.9 MASKS & SERUM 298
    • 11.14.10 CLEANSER 298
    • 11.14.11 OTHERS 298
  • 11.15 MULTIPLE SCLEROSIS 299
    • 11.15.1 OIL 300
    • 11.15.2 DRIED MEDICAL CANNABIS 300
    • 11.15.3 MEDICAL CANNABIS CAPSULES 300
    • 11.15.4 PATCH 300
    • 11.15.5 GROUND FLOWER 300
    • 11.15.6 CREAMS & MOISTURIZER 301
    • 11.15.7 VAPE PEN 301
    • 11.15.8 WHOLE FLOWER 301
    • 11.15.9 MASKS & SERUM 301
    • 11.15.10 CLEANSER 301
    • 11.15.11 OTHERS 301
  • 11.16 AUTISM 301
    • 11.16.1 OIL 302
    • 11.16.2 DRIED MEDICAL CANNABIS 302
    • 11.16.3 MEDICAL CANNABIS CAPSULES 303
    • 11.16.4 PATCH 303
    • 11.16.5 GROUND FLOWER 303
    • 11.16.6 CREAMS & MOISTURIZER 303
    • 11.16.7 VAPE PEN 303
    • 11.16.8 WHOLE FLOWER 303
    • 11.16.9 MASKS & SERUM 303
    • 11.16.10 CLEANSER 303
    • 11.16.11 OTHERS 303
  • 11.17 MENTAL HEALTH CONDITIONS 303
    • 11.17.1 MENTAL HEALTH CONDITIONS, BY TYPE 304
      • 11.17.1.1 POSTTRAUMATIC STRESS DISORDER (PTSD) 304
      • 11.17.1.2 SCHIZOPHRENIA 304
      • 11.17.1.3 OTHERS 304
    • 11.17.2 MENTAL HEALTH CONDITIONS, BY TYPE 305
      • 11.17.2.1 OIL 305
      • 11.17.2.2 DRIED MEDICAL CANNABIS 305
      • 11.17.2.3 MEDICAL CANNABIS CAPSULES 305
      • 11.17.2.4 PATCH 305
      • 11.17.2.5 GROUND FLOWER 305
      • 11.17.2.6 CREAMS & MOISTURIZER 306
      • 11.17.2.7 VAPE PEN 306
      • 11.17.2.8 WHOLE FLOWER 306
      • 11.17.2.9 MASKS & SERUM 306
      • 11.17.2.10 CLEANSER 306
      • 11.17.2.11 OTHERS 306
  • 11.18 ELEVATE MOOD 306
    • 11.18.1 OIL 307
    • 11.18.2 DRIED MEDICAL CANNABIS 307
    • 11.18.3 MEDICAL CANNABIS CAPSULES 308
    • 11.18.4 PATCH 308
    • 11.18.5 GROUND FLOWER 308
    • 11.18.6 CREAMS & MOISTURIZER 308
    • 11.18.7 VAPE PEN 308
    • 11.18.8 WHOLE FLOWER 308
    • 11.18.9 MASKS & SERUM 308
    • 11.18.10 CLEANSER 308
    • 11.18.11 OTHERS 308
  • 11.19 OTHERS 309

12 GLOBAL MEDICAL CANNABIS MARKET, BY ROUTE OF ADMINISTRATION 310

  • 12.1 OVERVIEW 311
  • 12.2 ORAL SOLUTIONS AND CAPSULES 314
  • 12.3 SMOKING 315
  • 12.4 TOPICALS 315
  • 12.5 VAPORIZERS 316
  • 12.6 OTHERS 317

13 GLOBAL MEDICAL CANNABIS MARKET, BY TREATMENT TYPE 318

  • 13.1 OVERVIEW 319
  • 13.2 ANALGESIC 322
  • 13.3 PSYCHEDELIC 322
  • 13.4 ANTIVIRAL 323
  • 13.5 APHRODISIAC 324
  • 13.6 EXPECTORANT 324
  • 13.7 OTHERS 325

14 GLOBAL MEDICAL CANNABIS MARKET, BY END USER 326

  • 14.1 OVERVIEW 327
  • 14.2 HOMECARE SETTING 330
  • 14.3 HOSPITAL 330
  • 14.4 REHAB CENTERS 331
  • 14.5 PHARMACEUTICAL INDUSTRY 332
  • 14.6 RESEARCH AND DEVELOPMENT CENTERS 333
  • 14.7 OTHERS 333

15 GLOBAL MEDICAL CANNABIS MARKET, BY DISTRIBUTION CHANNEL 334

  • 15.1 OVERVIEW 335
  • 15.2 B2C 338
    • 15.2.1 PHARMACIES 339
    • 15.2.2 CONVENTIONAL STORES 339
    • 15.2.3 ONLINE STORES 339
    • 15.2.4 OTHERS 339
  • 15.3 B2B 339

16 GLOBAL MEDICAL CANNABIS MARKET, BY REGION 340

  • 16.1 OVERVIEW 341
  • 16.2 NORTH AMERICA 347
    • 16.2.1 U.S. 374
    • 16.2.2 CANADA 404
    • 16.2.3 MEXICO 430
  • 16.3 EUROPE 452
    • 16.3.1 GERMANY 480
    • 16.3.2 ITALY 502
    • 16.3.3 U.K. 524
    • 16.3.4 AUSTRIA 545
    • 16.3.5 POLAND 567
    • 16.3.6 LITHUANIA 589
    • 16.3.7 IRELAND 611
    • 16.3.8 NETHERLANDS 633
    • 16.3.9 NORWAY 655
    • 16.3.10 SWITZERLAND 677
    • 16.3.11 FRANCE 699
    • 16.3.12 RUSSIA 721
    • 16.3.13 SPAIN 743
    • 16.3.14 HUNGARY 766
    • 16.3.15 BELGIUM 788
    • 16.3.16 TURKEY 810
    • 16.3.17 REST OF EUROPE 832
  • 16.4 ASIA-PACIFIC 833
    • 16.4.1 AUSTRALIA 872
    • 16.4.2 THAILAND 905
    • 16.4.3 SOUTH KOREA 938
    • 16.4.4 JAPAN 971
    • 16.4.5 CHINA 1004
    • 16.4.6 NEW ZEALAND 1037
    • 16.4.7 SINGAPORE 1070
    • 16.4.8 INDIA 1103
    • 16.4.9 TAIWAN 1136
    • 16.4.10 MALAYSIA 1169
    • 16.4.11 PHILIPPINES 1202
    • 16.4.12 REST OF ASIA-PACIFIC 1235
  • 16.5 SOUTH AMERICA 1236
    • 16.5.1 BRAZIL 1263
    • 16.5.2 ARGENTINA 1284
    • 16.5.3 PERU 1305
    • 16.5.4 REST OF SOUTH AMERICA 1328
  • 16.6 MIDDLE EAST AND AFRICA 1329
    • 16.6.1 ISRAEL 1355
    • 16.6.2 SOUTH AFRICA 1376
    • 16.6.3 LEBANON 1398
    • 16.6.4 U.A.E. 1419
    • 16.6.5 KUWAIT 1441
    • 16.6.6 REST OF MIDDLE EAST AND AFRICA 1462

17 GLOBAL MEDICAL CANNABIS MARKET: COMPANY LANDSCAPE 1463

  • 17.1 COMPANY SHARE ANALYSIS: GLOBAL 1463
  • 17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 1464
  • 17.3 COMPANY SHARE ANALYSIS: EUROPE 1465
  • 17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 1466

18 COMPANY PROFILE 1467

  • 18.1 MEDIPHARM LABS INC. 1467
    • 18.1.1 COMPANY SNAPSHOT 1467
    • 18.1.2 REVENUE ANALYSIS 1468
    • 18.1.3 COMPANY SHARE ANALYSIS 1468
    • 18.1.4 PRODUCT PORTFOLIO 1469
    • 18.1.5 RECENT DEVELOPMENTS 1469
  • 18.2 TILRAY 1471
    • 18.2.1 COMPANY SNAPSHOT 1471
    • 18.2.2 COMPANY SHARE ANALYSIS 1471
    • 18.2.3 PRODUCT PORTFOLIO 1472
    • 18.2.4 RECENT DEVELOPMENTS 1472
  • 18.3 AURORA CANNABIS 1473
    • 18.3.1 COMPANY SNAPSHOT 1473
    • 18.3.2 REVENUE ANALYSIS 1473
    • 18.3.3 COMPANY SHARE ANALYSIS 1474
    • 18.3.4 PRODUCT PORTFOLIO 1474
    • 18.3.5 RECENT DEVELOPMENTS 1474
  • 18.4 JAZZ PHARMACEUTICALS INC. (GW PHARMACEUTICALS PLC) 1476
    • 18.4.1 COMPANY SNAPSHOT 1476
    • 18.4.2 REVENUE ANALYSIS 1476
    • 18.4.3 COMPANY SHARE ANALYSIS 1477
    • 18.4.4 PRODUCT PORTFOLIO 1477
    • 18.4.5 RECENT DEVELOPMENTS 1477
  • 18.5 HEXO CORP. (ZENABIS GLOBAL LTD) 1479
    • 18.5.1 COMPANY SNAPSHOT 1479
    • 18.5.2 REVENUE ANALYSIS 1479
    • 18.5.3 COMPANY SHARE ANALYSIS 1480
    • 18.5.4 PRODUCT PORTFOLIO 1480
    • 18.5.5 RECENT DEVELOPMENTS 1481
  • 18.6 APOTHECANNA 1482
    • 18.6.1 COMPANY SNAPSHOT 1482
    • 18.6.2 PRODUCT PORTFOLIO 1482
    • 18.6.3 RECENT DEVELOPMENT 1483
  • 18.7 BOL PHARMA 1484
    • 18.7.1 COMPANY SNAPSHOT 1484
    • 18.7.2 PRODUCT PORTFOLIO 1484
    • 18.7.3 RECENT DEVELOPMENTS 1484
  • 18.8 BARNEY'S FARM 1485
    • 18.8.1 COMPANY SNAPSHOT 1485
    • 18.8.2 PRODUCT PORTFOLIO 1485
    • 18.8.3 RECENT DEVELOPMENTS 1486
  • 18.9 CANOPY GROWTH CORPORATION 1487
    • 18.9.1 COMPANY SNAPSHOT 1487
    • 18.9.2 REVENUE ANALYSIS 1487
    • 18.9.3 PRODUCT PORTFOLIO 1488
    • 18.9.4 RECENT DEVELOPMENTS 1488
  • 18.10 CANNABIS SEEDS USA 1490
    • 18.10.1 COMPANY SNAPSHOT 1490
    • 18.10.2 PRODUCT PORTFOLIO 1490
    • 18.10.3 RECENT DEVELOPMENT 1492
  • 18.11 CRESCO LABS 1493
    • 18.11.1 COMPANY SNAPSHOT 1493
    • 18.11.2 PRODUCT PORTFOLIO 1493
    • 18.11.3 RECENT DEVELOPMENTS 1495
  • 18.12 ECOGEN BIOSCIENCES 1496
    • 18.12.1 COMPANY SNAPSHOT 1496
    • 18.12.2 PRODUCT PORTFOLIO 1496
    • 18.12.3 RECENT DEVELOPMENTS 1496
  • 18.13 ELIXINOL GLOBAL LIMITED 1497
    • 18.13.1 COMPANY SNAPSHOT 1497
    • 18.13.2 REVENUE ANALYSIS 1497
    • 18.13.3 PRODUCT PORTFOLIO 1498
    • 18.13.4 RECENT DEVELOPMENTS 1498
  • 18.14 ENDOCA 1499
    • 18.14.1 COMPANY SNAPSHOT 1499
    • 18.14.2 PRODUCT PORTFOLIO 1499
    • 18.14.3 RECENT DEVELOPMENT 1499
  • 18.15 EXTRACTAS 1500
    • 18.15.1 COMPANY SNAPSHOT 1500
    • 18.15.2 PRODUCT PORTFOLIO 1500
    • 18.15.3 RECENT DEVELOPMENT 1500
  • 18.16 FOLIUM BIOSCIENCES 1501
    • 18.16.1 COMPANY SNAPSHOT 1501
    • 18.16.2 PRODUCT PORTFOLIO 1501
    • 18.16.3 RECENT DEVELOPMENTS 1502
  • 18.17 GREENWICH BIOSCIENCES, INC. 1503
    • 18.17.1 COMPANY SNAPSHOT 1503
    • 18.17.2 PRODUCT PORTFOLIO 1503
    • 18.17.3 RECENT DEVELOPMENTS 1503
  • 18.18 HARMONY 1504
    • 18.18.1 COMPANY SNAPSHOT 1504
    • 18.18.2 PRODUCT PORTFOLIO 1504
    • 18.18.3 RECENT DEVELOPMENTS 1504
  • 18.19 HUMBOLDT SEED COMPANY 1505
    • 18.19.1 COMPANY SNAPSHOT 1505
    • 18.19.2 PRODUCT PORTFOLIO 1505
    • 18.19.3 RECENT DEVELOPMENT 1506
  • 18.20 IDT AUSTRALIA 1507
    • 18.20.1 COMPANY SNAPSHOT 1507
    • 18.20.2 REVENUE ANALYSIS 1507
    • 18.20.3 PRODUCT PORTFOLIO 1508
    • 18.20.4 RECENT DEVELOPMENTS 1508
  • 18.21 MARY'S NUTRITIONALS, LLC 1510
    • 18.21.1 COMPANY SNAPSHOT 1510
    • 18.21.2 PRODUCT PORTFOLIO 1510
    • 18.21.3 RECENT DEVELOPMENT 1510
  • 18.22 MEDICAL MARIJUANA, INC. 1511
    • 18.22.1 COMPANY SNAPSHOT 1511
    • 18.22.2 REVENUE ANALYSIS 1511
    • 18.22.3 PRODUCT PORTFOLIO 1512
    • 18.22.4 RECENT DEVELOPMENTS 1512
  • 18.23 PEACE NATURALS PROJECT INC. 1513
    • 18.23.1 COMPANY SNAPSHOT 1513
    • 18.23.2 PRODUCT PORTFOLIO 1513
    • 18.23.3 RECENT DEVELOPMENT 1513
  • 18.24 PHARMAHEMP 1514
    • 18.24.1 COMPANY SNAPSHOT 1514
    • 18.24.2 PRODUCT PORTFOLIO 1514
    • 18.24.3 RECENT DEVELOPMENT 1514
  • 18.25 PURE RATIOS 1515
    • 18.25.1 COMPANY SNAPSHOT 1515
    • 18.25.2 PRODUCT PORTFOLIO 1515
    • 18.25.3 RECENT DEVELOPMENT 1515
  • 18.26 SEEDS FOR ME 1516
    • 18.26.1 COMPANY SNAPSHOT 1516
    • 18.26.2 PRODUCT PORTFOLIO 1516
    • 18.26.3 RECENT DEVELOPMENT 1516
  • 18.27 SEED CELLAR 1517
    • 18.27.1 COMPANY SNAPSHOT 1517
    • 18.27.2 PRODUCT PORTFOLIO 1517
    • 18.27.3 RECENT DEVELOPMENT 1518
  • 18.28 UPSTATE ELEVATOR SUPPLY CO. 1519
    • 18.28.1 COMPANY SNAPSHOT 1519
    • 18.28.2 PRODUCT PORTFOLIO 1519
    • 18.28.3 RECENT DEVELOPMENT 1519
  • 18.29 WORLD CLASS CANNABIS SEEDS (CROP KING SEEDS) 1520
    • 18.29.1 COMPANY SNAPSHOT 1520
    • 18.29.2 PRODUCT PORTFOLIO 1520
    • 18.29.3 RECENT DEVELOPMENT 1521

19 QUESTIONNAIRE 1522

20 RELATED REPORTS 1527

LIST OF FIGURES

  • FIGURE 1 GLOBAL MEDICAL CANNABIS MARKET: SEGMENTATION 169
  • FIGURE 2 GLOBAL MEDICAL CANNABIS MARKET: DATA TRIANGULATION 172
  • FIGURE 3 GLOBAL MEDICAL CANNABIS MARKET: DROC ANALYSIS 173
  • FIGURE 4 GLOBAL MEDICAL CANNABIS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 174
  • FIGURE 5 GLOBAL MEDICAL CANNABIS MARKET: COMPANY RESEARCH ANALYSIS 174
  • FIGURE 6 GLOBAL MEDICAL CANNABIS MARKET: INTERVIEW DEMOGRAPHICS 176
  • FIGURE 7 GLOBAL MEDICAL CANNABIS MARKET: DBMR MARKET POSITION GRID 177
  • FIGURE 8 GLOBAL MEDICAL CANNABIS MARKET: MARKET APPLICATION COVERAGE GRID 179
  • FIGURE 9 GLOBAL MEDICAL CANNABIS MARKET: VENDOR SHARE ANALYSIS 180
  • FIGURE 10 GLOBAL MEDICAL CANNABIS MARKET: SEGMENTATION 184
  • FIGURE 11 INCREASING MEDICINAL USE AND LEGALIZATION OF MEDICAL CANNABIS ARE EXPECTED TO DRIVE THE GLOBAL MEDICAL CANNABIS MARKET IN THE FORECAST PERIOD OF 2023 TO 2030 185
  • FIGURE 12 PRODUCT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL MEDICAL CANNABIS MARKET IN 2023 AND 2030 185
  • FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL MEDICAL CANNABIS MARKET AND IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2023 TO 2030 186
  • FIGURE 14 NORTH AMERICA IS THE FASTEST-GROWING MARKET FOR MEDICAL CANNABIS MANUFACTURERS IN THE FORECAST PERIOD OF 2023 TO 2030 187
  • FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL MEDICAL CANNABIS MARKET 206
  • FIGURE 16 GLOBAL MEDICAL CANNABIS MARKET: BY PRODUCT, 2022 214
  • FIGURE 17 GLOBAL MEDICAL CANNABIS MARKET: BY PRODUCT, 2023-2030 (USD MILLION) 215
  • FIGURE 18 GLOBAL MEDICAL CANNABIS MARKET: BY PRODUCT, CAGR (2023-2030) 216
  • FIGURE 19 GLOBAL MEDICAL CANNABIS MARKET: BY PRODUCT, LIFELINE CURVE 217
  • FIGURE 20 GLOBAL MEDICAL CANNABIS MARKET: BY SPECIES, 2022 247
  • FIGURE 21 GLOBAL MEDICAL CANNABIS MARKET: BY SPECIES, 2023-2030 (USD MILLION) 248
  • FIGURE 22 GLOBAL MEDICAL CANNABIS MARKET: BY SPECIES, CAGR (2023-2030) 248
  • FIGURE 23 GLOBAL MEDICAL CANNABIS MARKET: BY SPECIES, LIFELINE CURVE 249
  • FIGURE 24 GLOBAL MEDICAL CANNABIS MARKET: BY DERIVATIVES, 2022 254
  • FIGURE 25 GLOBAL MEDICAL CANNABIS MARKET: BY DERIVATIVES, 2023-2030 (USD MILLION) 255
  • FIGURE 26 GLOBAL MEDICAL CANNABIS MARKET: BY DERIVATIVES, CAGR (2023-2030) 255
  • FIGURE 27 GLOBAL MEDICAL CANNABIS MARKET: BY DERIVATIVES, LIFELINE CURVE 256
  • FIGURE 28 GLOBAL MEDICAL CANNABIS MARKET: BY APPLICATION, 2022 264
  • FIGURE 29 GLOBAL MEDICAL CANNABIS MARKET: BY APPLICATION , 2023-2030 (USD MILLION) 265
  • FIGURE 30 GLOBAL MEDICAL CANNABIS MARKET: BY APPLICATION , CAGR (2023-2030) 266
  • FIGURE 31 GLOBAL MEDICAL CANNABIS MARKET: BY APPLICATION, LIFELINE CURVE 266
  • FIGURE 32 GLOBAL MEDICAL CANNABIS MARKET: BY ROUTE OF ADMINISTRATION, 2022 311
  • FIGURE 33 GLOBAL MEDICAL CANNABIS MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION) 312
  • FIGURE 34 GLOBAL MEDICAL CANNABIS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030) 312
  • FIGURE 35 GLOBAL MEDICAL CANNABIS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 313
  • FIGURE 36 GLOBAL MEDICAL CANNABIS MARKET: BY TREATMENT TYPE, 2022 319
  • FIGURE 37 GLOBAL MEDICAL CANNABIS MARKET: BY TREATMENT TYPE, 2023-2030 (USD MILLION) 320
  • FIGURE 38 GLOBAL MEDICAL CANNABIS MARKET: BY TREATMENT TYPE, CAGR (2023-2030) 320
  • FIGURE 39 GLOBAL MEDICAL CANNABIS MARKET: BY TREATMENT TYPE, LIFELINE CURVE 321
  • FIGURE 40 GLOBAL MEDICAL CANNABIS MARKET: BY END USER, 2022 327
  • FIGURE 41 GLOBAL MEDICAL CANNABIS MARKET: BY END USER, 2023-2030 (USD MILLION) 328
  • FIGURE 42 GLOBAL MEDICAL CANNABIS MARKET: BY END USER, CAGR (2023-2030) 328
  • FIGURE 43 GLOBAL MEDICAL CANNABIS MARKET: BY END USER, LIFELINE CURVE 329
  • FIGURE 44 GLOBAL MEDICAL CANNABIS MARKET: BY DISTRIBUTION CHANNEL, 2022 335
  • FIGURE 45 GLOBAL MEDICAL CANNABIS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 336
  • FIGURE 46 GLOBAL MEDICAL CANNABIS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 336
  • FIGURE 47 GLOBAL MEDICAL CANNABIS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 337
  • FIGURE 48 GLOBAL MEDICAL CANNABIS MARKET: SNAPSHOT (2022) 342
  • FIGURE 49 GLOBAL MEDICAL CANNABIS MARKET: BY REGION (2022) 344
  • FIGURE 50 GLOBAL MEDICAL CANNABIS MARKET: BY REGION (2023 & 2030) 344
  • FIGURE 51 GLOBAL MEDICAL CANNABIS MARKET: BY REGION (2022 & 2030) 345
  • FIGURE 52 GLOBAL MEDICAL CANNABIS MARKET: BY PRODUCT (2023-2030) 345
  • FIGURE 53 NORTH AMERICA MEDICAL CANNABIS MARKET: SNAPSHOT (2022) 348
  • FIGURE 54 NORTH AMERICA MEDICAL CANNABIS MARKET: BY COUNTRY (2022) 350
  • FIGURE 55 NORTH AMERICA MEDICAL CANNABIS MARKET: BY COUNTRY (2023 & 2030) 350
  • FIGURE 56 NORTH AMERICA MEDICAL CANNABIS MARKET: BY COUNTRY (2022 & 2030) 351
  • FIGURE 57 NORTH AMERICA MEDICAL CANNABIS MARKET: BY PRODUCT (2023-2030) 351
  • FIGURE 58 EUROPE MEDICAL CANNABIS MARKET: SNAPSHOT (2022) 453
  • FIGURE 59 EUROPE MEDICAL CANNABIS MARKET: BY COUNTRY (2022) 455
  • FIGURE 60 EUROPE MEDICAL CANNABIS MARKET: BY COUNTRY (2023 & 2030) 455
  • FIGURE 61 EUROPE MEDICAL CANNABIS MARKET: BY COUNTRY (2022 & 2030) 456
  • FIGURE 62 EUROPE MEDICAL CANNABIS MARKET: BY PRODUCT (2023-2030) 456
  • FIGURE 63 ASIA-PACIFIC MEDICAL CANNABIS MARKET: SNAPSHOT (2022) 834
  • FIGURE 64 ASIA-PACIFIC MEDICAL CANNABIS MARKET: BY COUNTRY (2022) 836
  • FIGURE 65 ASIA-PACIFIC MEDICAL CANNABIS MARKET: BY COUNTRY (2023 & 2030) 836
  • FIGURE 66 ASIA-PACIFIC MEDICAL CANNABIS MARKET: BY COUNTRY (2022 & 2030) 837
  • FIGURE 67 ASIA-PACIFIC MEDICAL CANNABIS MARKET: BY PRODUCT (2023-2030) 837
  • FIGURE 68 SOUTH AMERICA MEDICAL CANNABIS MARKET: SNAPSHOT (2022) 1237
  • FIGURE 69 SOUTH AMERICA MEDICAL CANNABIS MARKET: BY COUNTRY (2022) 1239
  • FIGURE 70 SOUTH AMERICA MEDICAL CANNABIS MARKET: BY COUNTRY (2023 & 2030) 1239
  • FIGURE 71 SOUTH AMERICA MEDICAL CANNABIS MARKET: BY COUNTRY (2022 & 2030) 1240
  • FIGURE 72 SOUTH AMERICA MEDICAL CANNABIS MARKET: BY PRODUCT (2023-2030) 1240
  • FIGURE 73 MIDDLE EAST AND AFRICA MEDICAL CANNABIS MARKET: SNAPSHOT (2022) 1330
  • FIGURE 74 MIDDLE EAST AND AFRICA MEDICAL CANNABIS MARKET: BY COUNTRY (2022) 1332
  • FIGURE 75 MIDDLE EAST AND AFRICA MEDICAL CANNABIS MARKET: BY COUNTRY (2023 & 2030) 1332
  • FIGURE 76 MIDDLE EAST AND AFRICA MEDICAL CANNABIS MARKET: BY COUNTRY (2022 & 2030) 1333
  • FIGURE 77 MIDDLE EAST AND AFRICA MEDICAL CANNABIS MARKET: BY PRODUCT (2023-2030) 1333
  • FIGURE 78 GLOBAL MEDICAL CANNABIS MARKET: COMPANY SHARE 2022 (%) 1463
  • FIGURE 79 NORTH AMERICA MEDICAL CANNABIS MARKET: COMPANY SHARE 2022 (%) 1464
  • FIGURE 80 EUROPE MEDICAL CANNABIS MARKET: COMPANY SHARE 2022 (%) 1465
  • FIGURE 81 AISA-PACIFIC MEDICAL CANNABIS MARKET: COMPANY SHARE 2022 (%) 1466